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THE EFFECTS OF GLYCATION ON THE BINDING OF HUMAN
SERUM ALBUMIN TO WARFARIN AND L-TRYPTOPHAN
K.S. Joseph and David S. Hage*
Chemistry Department, University of Nebraska, Lincoln Lincoln, NE 68588-0304 (USA)
Abstract
Diabetes leads to elevated levels of glucose in blood which, in turn, can lead to the non-enzymatic
glycation of serum proteins such as human serum albumin (HSA). It has been suggested that this
increase in glycation can alter the ability of HSA to bind to drugs and other small solutes. This
study used high-performance affinity chromatography (HPAC) to see if there is any significant
change related to glycation in the binding of HSA to warfarin and L-tryptophan, which are often
used as probe compounds for Sudlow sites I and II of HSA in drug binding studies with this
protein. It was found through frontal analysis studies that both of these compounds gave a good fit
to a single-site binding model with glycated HSA under the conditions used in this study. There
were was no significant change in the association equilibrium constants or specific activities for
warfarin with HSA at pH 7.4 and 37°C under glycation conditions that were representative of
those expected in pre-diabetes or diabetes, but a 4.7–5.8 fold increase binding affinity for L-
tryptophan with glycated HSA was observed. These results indicate that warfarin and L-
tryptophan can be successively used as site-selective probes for glycated HSA; however, changes
in the affinity of L-tryptophan may need to be considered in such an application. These results
should be valuable in future competition studies using these compounds as probes to examine the
interactions of other drugs and solutes with Sudlow sites I and II and to determine how changes in
HSA glycation can affect the serum protein-binding of various pharmaceutical agents during
diabetes.
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1. Introduction
Diabetes is a growing problem in the United States. In 2007, over 23 million people within
the U.S. (7.8% of the population) were reported to have this disease, with over 1 million
people being diagnosed every year [1]. The most common form of this disease is type 2
(non-insulin dependent) diabetes, in which the body suffers from a shortage of insulin.
Diabetes is characterized by an elevated level of glucose in the blood. This glucose can form
covalent adducts with proteins in blood through a non-enzymatic process known as
glycation [2–4]. For example, glycated hemoglobin is now commonly used by physicians to
monitor the long-term control of diabetes by a patient [4]. However, many other blood
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proteins also become glycated including human serum albumin (HSA). Because HSA has a
shorter half-life than hemoglobin in blood, monitoring the extent of HSA glycation has been
considered as a way to look at short-term diabetes management [4].
HSA is the most prominent protein in human plasma. This protein is synthesized in the liver
and contains 585 amino acids with a total molar mass of 66,438 Da [5–7]. Two-thirds of
HSA is made up of α-helix structures while 10% of the protein contains β-turns. This protein
has three homologous domains (I, II, and III) that each contain two subunits (A and B).
Approximately 6–13% of this protein is glycated in normal individuals [2–5], but this level
can increase to over 20–30% in individuals with diabetes [3–5]. Glycation occurs by a
condensation reaction of glucose with a lysine residue or the N-terminus of HSA to first
form a Schiff base [3,6–8]. Rearrangements of this product create a ketoamine (i.e., an
Amadori product) [3,6,8]. Further rearrangements of this adduct can create advanced
glycation end-products (AGEs). Increased levels of these adducts and products can lead to
severe health complications in diabetic individuals [3].
HSA is a major transport protein in blood for carrying various endogenous and exogenous
compounds throughout the body. It greatly influences drug distribution and can play a major
role in affecting drug absorption, distribution, metabolism, and excretion [2,9–11]. Binding
to HSA also allows hydrophobic drugs to be more soluble in blood and increases the overall
lifetime of a drug before it is metabolized [2,11]. It has previously been determined that
HSA has two major binding sites for drugs (i.e., Sudlow sites I and II, located in subunits
IIA and IIIB of HSA), as well as additional minor binding sites [12–14]. Sudlow site I binds
anticoagulant drugs such as warfarin and anti-inflammatory drugs such as azapropazone,
phenylbutazone, and salicylate. Sudlow site II binds drugs such as ibuprofen, fenoprofen,
ketoprofen, and benzodiazepines, along with the essential amino acid L-tryptophan [9].
The purpose of this study was to see if the binding of HSA to warfarin and L-tryptophan
(see structures in Figure 1) is altered as the level of HSA glycation is increased, as occurs in
diabetes. Warfarin and L-tryptophan were of interest to this work because they are often
used as site-selective probes for Sudlow sites I and II, respectively, in examining the binding
of other drugs to HSA at these sites [15–17]. Glycation has noted in previous work to occur
at locations that are near both Sudlow sites I and II [2,3,8,16,17]. It has been suggested in
earlier studies based on fluorescence spectroscopy or equilibrium dialysis that the binding of
HSA to some drugs and other solutes [5,18,19], including both warfarin [4,5] and L-
tryptophan [18], can be affected by modifications resulting from glycation. However, past
studies examining the binding of warfarin with glycated HSA at 20–25°C have resulted in
apparently conflicting results, in which some authors have reported an increase in binding
strength while others reported a decrease [4,5]. Studies with L-tryptophan and glycated HSA
at 4°C found cases in which there was decreased and increased binding as the levels of
glycation were increased [18]. It is apparent from these results that there is still a need for a
better understanding of how glycation affects the binding of both warfarin and L-tryptophan
with glycated HSA. Because these previous studies were conducted at 4–25°C and using
non-physiological levels of HSA or glucose [4,5,19], there is also a need for further binding
studies under the temperature and concentration conditions that are more typical of those
expected in blood during diabetes.
The goal of this current study was to obtain binding information on these probe compounds
by using high-performance affinity chromatography (HPAC). HPAC is a chromatographic
technique that can make use of an immobilized protein (e.g., HSA) to provide a precise,
reproducible, and convenient means of examining drug-protein binding, while also being
capable of automation [20]. This approach has been utilized successfully in the past to
obtain drug-protein binding data on interactions of both warfarin and L-tryptophan with
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normal HSA [21–24]. This current report employed HPAC to also examine the interactions
of these solutes with in vitro glycated HSA. This was accomplished by preparing HPAC
columns that contained HSA with various known levels of glycation. The binding
parameters that were found with warfarin and L-tryptophan on these columns were then
compared to those noted with normal HSA. Knowledge of how these interactions are
affected by glycation should be valuable in future work that uses warfarin or L-tryptophan
as probes to examine the binding of other drugs of solutes with glycated HSA. This
information, in turn, could be important in the future in obtaining a better picture of how
such compounds bind to serum proteins such as HSA during diabetes and in how these
interactions affect properties such as the metabolism, excretion and distribution of these
drugs in this disease state.
2. Materials and Methods
2.1 Materials
Racemic warfarin (98% pure), L-tryptophan (98%), monobasic and dibasic potassium
phosphate salts, D-(+)-glucose (99.5%), sodium azide (>95%), acetohexamide, sodium
chloride, sodium nitrate, sodium phosphate salts, HSA (essentially fatty acid free albumin
from human serum, ≥ 96%), and in vitro glycated HSA (Lot 058K6087, referred to here as
“gHSA1”) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Reagents used in the
bicinchoninic acid (BCA) protein assay were from Pierce (Rockford, IL, USA). Nucleosil
Si-300 silica (300 Å pore size, 7 micron particle diameter) was obtained from Macherey-
Nagel (Düren, Germany). The enzymatic assay kits for fructosamine were from Diazyme
Laboratories (San Diego, CA, USA). Sterilized 17 × 100 mm culture tubes were purchased
from Fisher Scientific (Pittsburg, PA, USA). Slide-A-Lyzer 7K dialysis cassettes (7 kDa
MW cutoff; 0.5–3, 3–12, and 12–30 ml sample volume) were acquired from Thermo
Scientific (Rockford, IL, USA). Econo-Pac 10 DG disposable chromatography desalting
columns were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Solutions were
made using water from a Nanopure system (Barnstead, Dubuque, IA, USA) and filtered with
a 0.20 μm GNWP nylon membrane from Millipore (Billerica, MA, USA).
2.2 Apparatus
The chromatographic system consisted of a Jasco DG-2080-53 three-solvent degasser
(Tokyo, Japan), two Jasco PU-2080 isocratic HPLC pumps, a Rheodyne Advantage PF six-
port valve (Cotati, CA, USA), a Jasco AS-2055 autosampler, a Jasco CO-2060 column oven
(i.e., to maintain a column temperature of 37 °C), and a Jasco UV-2075 UV/Vis detector.
This chromatographic system hardware was controlled through EZChrom Elite software
v3.2.1 (Agilent, CA, USA) and a Jasco LC Net component. The chromatographic data were
analyzed using in-house programs written using Labview 5.1 software (National
Instruments, Austin, TX, USA) or using Peakfit 4.12 (Jandel Scientific Software, San
Rafael, CA, USA). Linear regression was performed using Excel 2003 (Microsoft
Corporation, Redmond, WA, USA) and non-linear regression was performed using DataFit
(Oakdale Engineering, PA, USA).
2.3 Methods
2.3.1. Preparation of Glycated HSA—Studies were performed using three different
glycated HSA samples. The first of which was purchased from a commercial source (Sigma-
Aldrich), and the other two glycated HSA samples were made in vitro using a modified
version of previously published methods [23,24]. To perform in vitro glycation of the HSA
samples, all glassware and spatulas that would come in contact with the glycated HSA
solution were previously sterilized by autoclaving to prevent bacterial growth during the
preparation of the glycated HSA. One liter of pH 7.4, 0.2 M potassium phosphate buffer was
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prepared and also sterilized by autoclaving to minimize bacterial growth during this process.
Sodium azide (i.e., a strong antibacterial agent) was added to this buffer once it had cooled
to make a 1 mM solution of this agent. A 15 mM or 30 mM glucose solution (used to make
gHSA2 and gHSA3, respectively, as described later in this report), was prepared using the
sterilized sodium azide solution, with 20 ml of this solution then being utilized to dissolve
840 mg of HSA to provide a working solution containing 42 g/L, or 0.63 mM, HSA. This
concentration of HSA was within the typical range (35–50 g/L, or 0.53–0.75 mM) seen in
humans under normal physiological conditions [2,21,22].
This HSA solution was placed into a series of sterile culture tubes as 3–4 ml fractions,
covered with the culture tube cap, further sealed with parafilm, and incubated in a water bath
at 37 °C for four weeks (i.e., a time interval equal to approximately two half-lives for HSA
in the circulation) [23]. After this incubation period, each glycated HSA solution was passed
through a size-exclusion desalting column to separate the protein from any excess glucose
and sodium azide in the solution. The collected protein fraction was dialyzed against water
to remove any remaining glucose and buffer salts. The water used during dialysis was 200–
500 times the volume of the sample. The sample was placed into a sterile dialysis cassette
and allowed to dialyze for 2 h at room temperature, with gentle stirring using a magnetic stir
bar, followed by a second dialysis cycle against water for another 2 h under the same
conditions. The sample was then dialyzed against water a third time, without stirring, at 4 °C
for approximately 14–18 h. The final samples were stored at −80 °C. Lyophilization was
performed until samples were completely dry. Samples were again stored at −80 °C until
use.
2.3.2. Fructosamine Assay—A commercial fructosamine assay from Diazyme was
modified for use in determining the overall level of glycation of each batch of HSA that was
used in this study. A 0.85% (w/v) saline solution was first prepared by dissolving 0.85 g
sodium chloride in 100 ml of water. A pH 7.4, 0.025 M sodium phosphate buffer was also
prepared. Although normal HSA concentrations in serum are around ~40 g/L [2], an HSA
sample solution of ~20 g/L was prepared to stay within the linear range of the assay (i.e.,
30–1354 μmol/L or 2–90 g/L). Each sample of glycated HSA for this assay was prepared by
weighing out roughly 10 mg of this protein and adding 500 μL of pH 7.4, 0.025 M sodium
phosphate buffer, followed by the solution then being placed on a vortex mixer for a short
period of time. A temperature-controlled UV/vis spectrometer was used to perform the assay
with the temperature held at 37 °C for the entire duration. A 300 μL portion of Reagent 1
from the kit was added to an empty cuvette. A 30 μL portion of the sample was then added,
the resulting solution was mixed quickly, and placed into the spectrometer, with absorbance
measurements being taking after 5 min at 600 and 700 nm. A 75 μL portion of Reagent 2
from the kit was then added to the cuvette and mixed quickly with the other contents, with
this mixture then being allowed to react for 5 min before measurements were again taken at
600 and 700 nm. Each sample was run in duplicate or triplicate. A 0.85% (w/v) saline
solution was used as a blank to subtract out the background while calibration standards and a
control were measured during this assay; this procedure was repeated several times using
these solutions in place of a 30 μL sample. The difference in the absorbance readings at 600
nm and 700 nm was calculated at each time, and the difference in the resulting values for the
first and second 5 min readings was then also found. A calibration curve was made per the
manufacturer’s instructions using a calibration standard included with the kit. This gave a
plot that was used to find the μmol of fructosamine (i.e., a value equivalent to μmol hexose)
in each protein sample.
2.3.3. HPAC Column and Solution Preparation—Nucleosil Si-300 silica was used to
prepare diol-bonded silica according to a previously published procedure [25]. Glycated
HSA was immobilized to the resulting support by using the Schiff base method, as
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previously discussed for normal HSA; and a control support was made in the same manner
but with no glycated HSA being added during the immobilization step [17]. It should be
noted here that although both the Schiff base immobilization and glycation involve free
amine residues, previous studies have determined that these process mainly involve different
residues on HSA, with the Schiff base method predominantly using the N-terminus or a few
lysines that are not present at Sudlow sites I or II [26,27]. As a result, the prior glycation of
HSA should not have affected the ability of this protein to be immobilized by the Schiff base
method or the relative activities noted at Sudlow sites I and II for this immobilized protein,
as was confirmed later in this study (see Section 3). A BCA assay was performed in
triplicate to determining the content of each support, using soluble glycated HSA as the
standard and the control support as the blank. The protein content of gHSA 1, 2, and 3
samples were found by this method to be 29 (± 4), 47 (± 8), and 40 (± 3) mg HSA/g silica,
respectively (see Table 1). Each glycated HSA silica sample was downward slurry-packed
into separate 2.0 cm x 2.1 mm I.D. columns at 3500 psi (24.1 MPa) using pH 7.4, 0.067 M
potassium phosphate buffer as the packing solution. A column with the same dimensions but
packed with the control support was also prepared. All columns were stored at 4 °C in pH
7.4, 0.067 M potassium phosphate buffer and were used over the course of one year and for
fewer than 500 sample applications or injections per column. HSA columns have been
shown in previous studies to retain good stability for drug-protein binding studies under
such conditions [17].
The warfarin, L-tryptophan and all other sample solutions for the chromatographic studies
were prepared in pH 7.4, 0.067 M potassium phosphate buffer. The same pH 7.4, 0.067 M
potassium phosphate buffer was used as the application and elution in the chromatographic
studies. All solutions were filtered through a 0.2 μm nylon filter and degassed under vacuum
for at least 15 min prior to use. Solutions of L-tryptophan have been found to decrease in
stability over 2–9 days (depending on storage conditions) [16], so for this work the L-
tryptophan solutions were made fresh daily prior to use. Racemic warfarin has been shown
to have a slow structural conversion over time from its minor cyclic hemiketal to its major
cyclic hemiketal [28]. When stored at 5 °C, a 5% conversion occurs in 45–52 hours whereas
95% conversion occurs between 109–127 days. Warfarin solutions were stored at 4 °C and
used within 10 days for these experiments. All chromatographic experiments described in
this report were performed at 37.0 (±0.1) °C. The elution of R-warfarin and L-tryptophan
was monitored at 308 nm and 280 nm, respectively, while sodium nitrate (i.e., a non-
retained solute) was monitored at 205 nm.
2.2.4. Chromatographic Studies—The competition studies described later in this report
were conducted by using zonal elution on the columns containing normal HSA or glycated
HSA. These studies were conducted using varying concentrations of acetohexamide (0–20
μM) in the mobile phase while 20 μL of R-warfarin or L-tryptophan were injected on to the
column at a concentration of 5 μM. These studies were performed for the HSA or gHSA
columns and corresponding control columns. Sodium nitrate was used to determine the void
time of the columns and the system by injecting 20 μL of 20 μM sodium nitrate onto each
column and injecting it onto the system with a zero-volume union. A pH 7.4, 0.067 M
potassium phosphate buffer was used to make all solutions. PeakFit v.4.12 and an
exponentially-modified Gaussian curve fit were used to determine the central moments of
the eluting peaks.
All frontal analysis experiments were carried out at 0.5 ml/min. This flow rate has been
shown in similar studies to obtain reproducible binding capacities with the given analytes
and on columns containing normal HSA [29,30]. The concentrations for the applied analyte
solutions ranged from 1 and 10 μM. A six-port injection valve was used to switch between
the mobile phases (i.e., sample application and elution/column regeneration). The column
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was first equilibrated using pH 7.4, 0.067 M potassium phosphate buffer. When performing
the frontal analysis experiments, the six-port valve was programmed to switch from this
buffer to the given analyte solution after one minute from time zero to ensure an initial
steady baseline for data analysis. Once the analyte had fully saturated the column and a
breakthrough curve had been obtained, the six-port valve was switched back to the original
pH 7.4 phosphate buffer to wash the retained analyte from the column and re-equilibrate the
column before the next run. All experiments were performed at each analyte concentration
on both the glycated HSA columns and the control column. The resulting breakthrough
curves were analyzed using Labview 5.1 or Peakfit v.4.12 and were corrected for non-
specific binding by the analytes to the support by subtracting control column data from data
for the glycated HSA columns.
3. Results and Discussion
3.1 Preparation and Initial Studies of Glycated HSA
One issued noted with previous studies looking at warfarin or L-tryptophan interactions with
glycated HSA is that the conditions employed in such work differed significantly in one or
more ways from those expected within the body. For instance, these earlier reports [4,5,19]
examined binding at 4°C or 20–25°C rather than at a physiological temperature of 37°C, as
used in this current report. In addition, many of these earlier reports used a much smaller
concentration of HSA than is present in the circulation (e.g., 0.075 or 0.3 mM HSA in Refs.
4 and 5 versus a typical serum level of 0.6–0.63 mM, as used in this current study and Ref.
18). These same studies also tended to use a much larger concentration and excess of
glucose versus HSA than would be expected in diabetes (e.g., a 165- to 3330-fold mol
excess of glucose versus HSA in Refs. 4 and 5 vs. up to the 48-fold excess in this study and
Ref. 18).
Three samples of in vitro glycated HSA were used in this study. The first preparation
(referred to here as gHSA1, and obtained from a commercial source) had a relatively low
level of glycation of 1.31 (± 0.05) mol hexose/mol HSA and was used to represent
minimally glycated HSA, as might be found during pre-diabetes or early state diabetes. The
second sample, gHSA2, was made using glucose conditions typical of those seen in diabetes
and had a glycation level of 2.34 (± 0.13) mol hexose/mol HSA [31]. The third sample,
referred to here as gHSA3, contained 3.35 (± 0.14) mol hexose/mol HSA and was used to
represent a case of uncontrolled, advanced diabetes. Protein assays were also conducted on
each of these preparations after they had been immobilized by the same method to HPLC
grade silica, giving final protein contents in the range of 29 to 47 mg protein/g silica, or
roughly 440 to 710 nmol glycated HSA/g silica. These latter results were in the same range
as seen for non-glycated HSA when using the same immobilization method and type of
support material [17,28].
Preliminary competition studies were first conducted with these supports using the method
of zonal elution. In these studies, similar retention factors (when corrected for differences in
column protein content) were noted for R-warfarin and L-tryptophan in the absence of any
competing agents. An example of such a study is shown in Figure 2 for columns containing
HSA or glycated HSA. In this type of study, the retention of these site-selective probe
compounds was examined while varying the concentration of a mobile phase additive and
possible competing agent (i.e., acetohexamide, in this case). In this type of experiment, Eqn.
(1) describes the predicted change in retention of the injected analyte (A) if it has
competition at a single type of site on an immobilized ligand with the competing agent (I).
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(1)
In this equation, the retention factor (k) is determined by using the retention time of the
analyte (tR) and the void time of the system (tM), where k = (tR – tM)/tM. The terms KaA and
KaI are the association equilibrium constants for the analyte and the competing agent,
respectively, at their site of competition on the immobilized ligand and VM is the void
volume. If direct competition is present between A and I at a single type of binding site, a
plot of 1/k versus [I] should be linear, as occurs for the plots in Figure 2. In addition the
value of k at the intercept will be directly related to the equilibrium constant and relative
activity of the immobilized ligand for the injected analyte (i.e., at [I] = 0, 1/k = VM/{KaA mL}
or k = KaA mL/VM).
The similarities of the retention factors noted when [I] = 0 in plots such as Figure 2 for the
normal HSA and glycated HSA columns suggested that warfarin and L-tryptophan (data not
shown) had relatively consistent binding to Sudlow sites I and II, respectively. This
appeared to be the case even though the competition of these probes with drugs like
acetohexamide did create a change in the response of these plots. Additional studies based
on frontal analysis were next undertaken (see following sections) to further examine the
interactions of warfarin and L-tryptophan with these columns prior to more in depth studies
using these compounds as probes in competition studies with additional drugs on glycated
HSA columns.
3.2 Binding of Warfarin to Glycated HSA
Frontal analysis studies were performed to obtain a more detailed analysis of the binding
parameters for glycated HSA with warfarin. This method is performed by continuously
applying a solution with a known amount of analyte to a column with an immobilized
ligand. As the analyte binds to the ligand, the column becomes saturated and a characteristic
breakthrough curve is formed (Figure 3). A breakthrough time can be calculated when the
area under the first half of the curve equals the area above the second half of the curve [20].
The middle point represents the breakthrough time. When fast association/dissociation
kinetics are present, the breakthrough time can be related to the concentration of the analyte
[A], the association equilibrium constant for the analyte-ligand system (Ka), and the moles
of active binding sites on the column for the analyte (mL). The following equations show
this relationship for a system where there is a single type of binding site on the ligand for the
analyte (single-site model) [20],
(2)
(3)
in which mLapp is the apparent moles of analyte that are required to reach the mean position
of the breakthrough curve at any given concentration of applied analyte and [A] is the molar
concentration of the applied analyte. Eqn. (3) would be expected to produce a linear
relationship for a 1:1 binding model when a plot is made of 1/mLapp versus 1/[A], while a
non-linear fit and a plot of mLapp versus [A] would be used when applying Eqn. (2) to the
Joseph and Hage Page 7
J Pharm Biomed Anal. Author manuscript; available in PMC 2011 November 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
same data. Either type of fit make it possible to determine Ka and mL simultaneously for the
interaction, which can be used to provide information on how a change in the ligand might
affect its affinity or relative activity for the applied analyte [32]. In this current study, this
approach was used to monitor any changes that occurred in binding as the degree of
glycation was varied for HSA.
Some typical frontal analysis results that were obtained for warfarin on the glycated HSA
columns are shown in Figures 3 and 4. In each case, warfarin produced breakthrough curves
that shifted to shorter breakthrough times as the concentration of the applied analyte was
increased (see Figure 3). The data obtained from these breakthrough curves were then
analyzed according to Eqn. (2). Some typical results are shown in Figure 4. It was found for
each of the glycated HSA columns that there was good agreement with the linear behavior
predicted by Eqn. (3) at the concentration range which was examined in this study. The
correlation coefficients ranged from 0.997 to 0.998 (n = 5), with only random variations
generally being noted in the data points about the best-fit line (Note: a small amount of
curvature may have been present in the results for the gHSA3 column, but using a higher-
order fit such as a two-site model did not give any further improvement in the quality of the
overall fit to this set of results). Similar agreement between the data and a one-site binding
model was obtained when fitting a plot of mLapp versus [A] according to Eqn. (2), as
demonstrated in Figure 5. These results agreed with those of previous examining the binding
of warfarin with glycated HSA at 20–25°C, which also noted a good fit to a single site
binding model [4,5].
Table 2 summarizes the association equilibrium constants that were obtained when the
plotting the data according to Eqn. (3) and using a single-site model. These values ranged
from 2.3 × 105 M−1 to 2.7 × 105 M−1 and had relative precisions of ± 9–10%. These results
did not show any significant variations at the 95% confidence level between the various
glycated HSA columns that were examined in this study, with all Ka values agreeing within
17–20% and within ± 2 S.D. of any other Ka value for warfarin in this same data set. This
range of values also agreed within an average association equilibrium constant of 2.4 (± 0.4)
× 105 M−1 that was determined based on previous results reported for the separate R- and S-
enantiomers of warfarin on a similar column that contained normal HSA and using the same
method of data analysis [29]. These results indicated glycation did not have any observable
effect on the average Ka that was measured for R/S-warfarin on these columns as the level of
glycation of HSA was increased up to the level present in the gHSA column (i.e., 3.35 mol
hexose/mol HSA, as shown in Table 1).
It was also possible from the results in Figure 4 to determine the binding capacity of each
affinity column for warfarin. This information was combined with the known protein
content to obtain the specific activity for warfarin on each column and to compare these
results to those expected for normal HSA. These results are also summarized in Table 2.
When normalized for the protein content, it was found that comparable specific activities
were present on each of the glycated HSA columns for warfarin. The relative precision of
these specific activities was ± 12–19% and all of these specific activities were within 11% of
all other values in this same data set. These values also ranged from 98% to 104% of the
activity expected for columns containing normal HSA (e.g., as determined by using Eqn. (1)
to analyze the results in Figure 2) and showed no significant variations at the 95%
confidence level. It was concluded from the results in Table 2 that there was no significant
change in either the association equilibrium constants or the relative activity of Sudlow site I
for warfarin in going from normal HSA to glycated HSA at the levels of glycation that were
examined in this study.
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The lack of any apparent change in warfarin binding to glycated HSA at 37°C under the
conditions used in this study falls between the conflicting conclusions reached in previous
studies at 20–25°C, noting either up to a 1.8-fold increase in the strength of this binding or a
6.9-fold decrease [4,5]. However, a much larger excess of glucose than employed in this
report was generally used to make the glycated HSA in these previous studies (i.e., up to a
165- to 3,300-fold mol excess of glucose compared to the 28- to 48-fold mol excess in this
report). It is suggested when comparing the results of all these studies that glycation
conditions that more closely mimic those occurring in blood will lead to fewer changes in
warfarin binding than seen using much harsher glycation conditions. The conclusion is
supported by the past use of circular dichroism to look for any major structural changes in
HSA after glycation. It was found when using a 33-fold mol excess of glucose during
glycation (i.e., a level similar to that used in this current report), no changes in secondary
structure were seen for glycated HSA versus normal HSA. However, the use of a 670-fold
mol excess of glucose during glycation did produce noticeable changes in the secondary
structure of HSA, which were believed to be linked in the change in warfarin-HSA binding
strength seen under such conditions [4,5].
3.3 Binding of L-Tryptophan to Glycated HSA
Similar frontal analysis studies to those in the previous section were conducted with L-
tryptophan to examine the binding of this compound to Sudlow site II as glycation levels on
HSA were increased. All of the tested columns gave results that gave a good fit to Eqn. (2)
under the conditions used in this study (see Figure 6). The correlation coefficients for all of
these plots was 0.999 (n = 5) and only random variations were noted in the data points about
the best-fit line. These results indicated that the binding of L-tryptophan with the various
samples of glycated HSA could be described effectively by a single-site when examined at
37°C. The same single site model has been shown in past studies to also give a good fit for
the binding of L-tryptophan with glycated HSA at 4°C [18].
Table 2 summarizes association equilibrium constants and relative activities that were
determined from the frontal analysis experiments for L-tryptophan with the various glycated
HSA columns. The Ka values for this solute ranged from 5.2 × 104 M−1 to 6.4 × 104 M−1
with relative precisions for these values of ± 9 to 26% (Figure 6). These Ka values for the
glycated HSA columns all overlapped within a range of 2 S.D. and were not significantly
different at the 95% confidence level. However, these values were all 4.7–5.8 times higher
than an association equilibrium constant of 1.1 × 104 M−1 that has been reported at 37°C for
L-tryptophan on similar columns containing normal HSA [30,33,34]. These results indicated
that even the levels seen in minimally-glycated HSA can affect the strength of L-tryptophan
interactions with this protein. Possible changes in the binding strength of L-tryptophan with
HSA versus glycated HSA have also been noted at 4°C under comparable glycation
conditions, although at this latter temperature up to a 0.6-fold decrease in affinity may have
been observed [18].
The measured binding capacities and the protein contents were used to also examine the
specific activity of L-tryptophan on each glycated HSA column. When the binding
capacities had been normalized for the amount of protein on the column, the specific
activities for L-tryptophan ranged between 30.5 and 36.5% on each column, with precisions
of ± 2–22%. These values differed by a maximum of only 16% and all fell within 1 S.D. of
the values of the other columns, showing no significant differences at the 95% confidence
level. These specific activities were also within the range that has been noted previously for
L-tryptophan on columns containing non-glycated HSA that were prepared by the same
immobilization method and on comparable silica supports [30]. It was concluded from these
data that the levels of glycation used in this report did not create any appreciable changes in
the specific activity of HSA for L-tryptophan.
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Conclusion
Uncontrolled diabetes increases blood sugar levels which in turn facilitate a boost in the
level of glycation that blood proteins undergo. This increase in glycation can potentially
alter the binding of drugs to the protein thereby changing the transport of the drug around
the body. These studies examined the binding at 37°C of warfarin and L-tryptophan for the
major drug binding sites on HSA (i.e., Sudlow sites I and II, respectively). For warfarin, a
good fit to a single-site model was noted for all samples of glycated HSA that were
examined. No significant changes in the association equilibrium constants or relatively
binding activities were seen for warfarin when comparing references values for normal HSA
with the results obtained for glycated HSA that was representative of conditions expected
during pre-diabetes or diabetes. The binding of L-tryptophan with glycated HSA also
showed good agreement with a single-site binding model. The association equilibrium
constants for L-tryptophan with even minimally-glycated HSA appeared to increase versus
reference values for normal HSA when working with even minimally-glycated HSA,
however, the specific activity of the glycated HSA for L-tryptophan was comparable to what
would be expected for normal HSA.
These findings indicate the warfarin and L-tryptophan can be used as probes for Sudlow
sites I and II in work with in vitro glycated HSA, although the changes in binding strength
for L-tryptophan should be considered in such an application. Similar studies are now in
progress with in vivo glycated HSA; changes due to glycation in drug binding with other
serum proteins is also of interest for future studies. The results of this current study should
be valuable in future competition studies using warfarin and L-tryptophan as probes to
examine the interactions of other drugs and solutes with Sudlow sites I and II on HSA. Such
information, in turn, should make it possible to better describe and predict how changes in
HSA glycation can affect the serum protein-binding and effective activity of various
pharmaceutical agents during diabetes.
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Figure 1.
Structures of warfarin and L-tryptophan.
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Figure 2.
(a) Competition studies for the injection of R-warfarin onto glycated HSA 1 column with
acetohexamide solutions in the mobile phase. Acetohexamide concentrations from left to
right: 20, 15, 10, 5, and 1 μM. The R-warfarin samples had a concentration of 5 μM and the
injection volume was 20 μL. (b) Plots of 1/k vs. [Acetohexamide] while injecting R-warfarin
on to a normal HSA column (●) and glycated HSA column 1 (■). The best-fit lines were as
follows: normal HSA, y = 779 (± 51) x + 0.0184 (± 0.0006) (r = 0.991); glycated HSA, y =
1075 (± 72) x + 0.0183 (± 0.0008) (r = 0.991).
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Figure 3.
Breakthrough curves for warfarin at applied concentrations 10, 5, 2.5, 1.5, and 1 μM (from
left to right) on glycated HSA column 1. Conditions for these studies are given in the text.
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Figure 4.
Double reciprocal plots prepared according to Eqn. (3) for warfarin binding to columns
prepared with samples of gHSA1 (▲), gHSA2 (■) or gHSA3 column (●). The solid line
shows the best-fit line for each data set. The error bars represent a range of ± 1 S.D. The
best-fit lines were as follows: gHSA1, y = 424 (± 15) x + [9.62 (± 0.87)] × 107 (r = 0.998);
gHSA2, y = 270 (± 10) x + [6.10 (± 0.56)] × 107 (r = 0.998); gHSA3, y = 287 (± 13) x +
[7.80 (± 0.77)] × 107 (r = 0.997).
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Figure 5.
Plots of mLapp versus [Warfarin] prepared according to Eqn. (2) for the gHSA1 column (▲),
gHSA2 column (■) and gHSA3 column (●). That data used in these plots were the same as
used in Figure 4. The best-fit lines were as follows: gHSA1, y = [{1.81 (± 0.15)} × 105 ×
{1.19 (± 0.05) × 10−8 x]/[1 + {1.81 (± 0.15)} × 105 x] (r = 0.999); gHSA2, y = [{1.89 (±
0.09)} × 105 × {1.83 (± 0.05) × 10−8 x]/[1 + {1.89 (± 0.09)} × 105 x] (r = 0.999); gHSA3, y
= [{2.01 (± 0.20)} × 105 × {1.52 (± 0.05) × 10−8 x]/[1 + {2.01 (± 0.20)} × 105 x] (r =
0.998).
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Figure 6.
Double reciprocal plots of L-tryptophan binding to affinity columns containing glycated
HSA. These results are for the gHSA1 column (▲), gHSA2 column (■), and gHSA3
column (●). The solid line shows the best-fit line for each data set. The error bars represent a
range of ± 1 S.D. The best-fit lines were as follows: gHSA1, y = [3.89 (± 0.06)] × 103 x +
[2.02 (± 0.36)] × 108 (r = 0.999); gHSA2, y = [2.34 (± 0.07)] × 103 x + [1.49 (± 0.39)] × 108
(r = 0.999); gHSA3, y = [3.04 (± 0.04)] × 103 x + [1.72 (± 0.16)] × 108 (r = 0.999).
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Table 1
Properties of glycated HSA supportsa
Type of support
gHSA1 gHSA2 gHSA3
Protein content (mg HSA/g silica) 29 (± 4) 47 (± 8) 40 (± 3)
Glycation level (mol hexose/mol HSA) 1.31 (± 0.05) 2.34 (± 0.13) 3.35 (± 0.14)
a
The values shown in parentheses represent a range of ± 1 S.D.
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Table 2
Binding parameters for R-warfarin and L-tryptophan on various HSA columns
Type of HSA column
Normal HSA gHSA1 gHSA2 gHSA3
Racemic Warfarin
 Ka (× 105 M−1) 2.4 (± 0.4)b 2.3 (± 0.2) 2.3 (± 0.2) 2.7 (± 0.3)
 mL (× 10−8 mol) ------- 1.04 (± 0.09) 1.64 (± 0.15) 1.28 (± 0.13)
 Specific Activity (mol/mol HSA) ------- 0.76 (± 0.12) 0.74 (± 14) 0.68 (± 0.09)
L-Tryptophan
 Ka (× 104 M−1) 1.1 (± 0.3)c 5.2 (± 0.9) 6.4 (± 1.7) 5.7 (± 0.5)
 mL (× 10−9 mol) ------- 5.0 (± 0.9) 6.7 (± 1.8) 5.8 (± 0.6)
 Specific Activity (mol/mol HSA) ------- 0.36 (± 0.08) 0.30 (± 0.05) 0.31 (± 0.04)
a
The values in parentheses represent a range of ± 1 S.D. The Ka and mL values shown were determined by using Eqn. 3. The values shown in
parentheses represent a range of ± 1 S.D.
b
The Ka value given for racemic warfarin was calculated based on data from Ref. [27].
c
The Ka value given for L-tryptophan was calculated based on data from Refs. [28,31].
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